Clinical, biochemical and immunological characteristics of relapsers and non-relapsers of thyrotoxicosis treated with anti-thyroid drugs

Journal of Internal Medicine

Volumn 244, Issue 4, 1998, Pages 293-297

  Chowdhury, T A ^a   Dyer, P H ^a  

^a BIRMINGHAM HEARTLANDS HOSPITAL   (United Kingdom)

Author keywords

Anti thyroid drugs; Relapse; Thyrotoxicosis

Indexed keywords

ANTITHYROID AGENT; CARBIMAZOLE; PROPYLTHIOURACIL; THYROXINE;

ADULT; AGE; ARTICLE; FREE THYROXINE INDEX; GOITER; HUMAN; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; QUESTIONNAIRE; RELAPSE; RETROSPECTIVE STUDY; SMOKING; TACHYCARDIA; THYROTOXICOSIS;

ADULT; ANTITHYROID AGENTS; CARBIMAZOLE; FEMALE; HUMANS; LOGISTIC MODELS; MALE; RECURRENCE; RETROSPECTIVE STUDIES; THYROID FUNCTION TESTS; THYROID HORMONES; THYROTOXICOSIS;

EID: 0031685362     PISSN: 09546820     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2796.1998.00320.x     Document Type: Article

References (17)

1. Tunbridge WMG, Evered DC, Hall R, Appleton D, Bruwis M, Clarke F et al. The spectrum of thyroid disease in a community. Clin Endocrinol 1997; 7: 481-93.
2. Hashizume K, Ichikawa K, Sakurai A, Suzuki S, Takeda T, Kobayashi M et al. Administration of thyroxine in treated Graves disease. Effects on the level of antibodies to thyroid stimulating hormone receptors and on the risk of recurrence of hyperthyroidism. N Engl J Med 1991; 324: 947-53.
3. Allanic H, Fauchet R, Orgiazzi J, Madec AM, Genetet B, Lorcy Y et al. Anti-thyroid drugs and Graves disease: a prospective randomised evaluation of the efficacy of treatment duration. J Clin Endocrinol Metab 1990; 70: 675-9.
4. Cooper DS. Anti-thyroid drugs. N Engl J Med 1984; 311: 1353-62.
5. Clinder D, Hesch D, Lagasse R, Laurberg P. The management of hyperthyroidism due to Graves disease in Europe in 1986. Results of an international survey. Acta Endocrinol (Copenh) 1987; 115: 1-23.
6. Thalassinos NC, Oakley NW, Russel-Fraser T. Five year follow up of thyrotoxicosis treated with anti-thyroid drugs. Endokrinologie 1974; 63: 325-30.
7. McIver B, Rae P, Beckett G, Wilkinson E, Gold A, Toft A. Lack of effect of thyroxine in patients with Graves hyperthyroidism who are treated with an anti-thyroid drug. N Engl J Med 1996; 334: 221-4.
8. Winsa B, Dahlberg PA, Jansson R, Agren M, Karlsson FA. Factors influencing the outcome of thyrostatic drug therapy in Graves' disease. Act Endocrinol (Copenh) 1990; 122: 622-8.
9. Weetman AP, Ratanachaiyavong S, Middleton GW, Love W, John R, Owen GM et al. Prediction of outcome in Graves' disease after carbimazole treatment. Q J Med 1986; 59: 409-19.
10. Takamatsu J, Kuma K, Mozai T. Serum triiodothyronine to thyroxine ratio: a newly recognised predictor of the outcome of hyperthyroidism due to Graves disease. J Clin Endo Metab 1986; 62: 980-3.
11. Shine B, Fells P, Edwards OH, Weetman AP. Association of Graves' ophthalmopathy and smoking. Lancet 1990; 335: 1261-3.
12. Allanic H, Faucet R, Lorey Y. HLA and Graves disease: an association with HLA DRW3. J Clin Endocrinol Metab 1980; 51: 863-7.
13. McGregor AM, Rees Smith B, Hall R, Peterson MM, Miller M, Dewar PJ. Prediction of relapse in hyperthyroid Graves Disease. Lancet 1980; 5: 1101-3.
14. Tabaiehi Y, Tanai H, Honda K, Nagai K, Kuma K, Nakagaura T. The significance of antithyroglobulin and anti-thyroid microsomal antibodies in patients with hyperthyroidism due to Graves disease treated with anti-thyroid drugs. J Clin Endocrinol Metab 1989;68: 1097-100.
15. Feldt-Rasmussen U, Schleusener H, Carayon P. Meta-analysis evaluation of the impact of thyrotropin receptor antibodies on long term remission after medical therapy of Graves' disease. J Clin Endo Metab 1994; 78: 98-102.
16. Knobel M, Borca MF, Pedrinola F, Medierog-Neto G. Prevalence of anti-thyroid peroxidase antibodies in autoimmune and non-autoimmune thyroid disorders in a relatively low iodine environment. J Endo Invest 1994; 17: 837-42.
17. Franklyn J, Sheppard M. Radioiodine for hyperthyroidism. Br Med J 1992; 305: 727-8.